Trial purpose
Cancer treatment
Tumor type
Genitourinary
Age
18+
Clinical summary
Summary
Eligible participants will be randomised to one of two experimental arms. In Arm A, participants will receive 177Lu-PSMA (7.5GBq, every 6 weeks up to 6 cycles), in combination with Ipilimumab (3mg/kg every 6 weeks, up to 4 doses) and Nivolumab (1mg/kg every 3 weeks, up to 8 doses), followed by Nivolumab monotherapy (480mg, every 4 weeks, up to 18 doses). In Arm B, participants will receive 177Lu-PSMA (7.5GBq) given every 6 weeks up to 6 cycles.
Conditions
This trial is treating people with metastatic, castration resistant prostate cancer
Eligibility
Inclusion
- Aged 18 years or older, with histologically confirmed adenocarcinoma of the prostate.
- Castration-resistant metastatic prostate cancer (defined as disease progressing despite castration by orchidectomy or ongoing luteinising hormone-releasing hormone agonist or antagonist).
-
Patients must have progressed on prior novel AR targeted agents for treatment of prostate cancer. Progressive disease defined by at least one of the following:
- PSA progression, minimum of two rising PSA values from a baseline measurement with an interval of ≥ 1 week between each measurement. The PSA value at screening should be ≥ 5ng/ml
- Soft tissue or visceral disease progression as per RECIST 1.1
- Bone progression: ≥ 2 new lesions on bone scan as per PCWG3
- Target or non-target lesions according to RECIST 1.1 and PCWG3
- Significant PSMA avidity on PET/CT using 68GaPSMA, defined as SUVmax ≥15 at a site of disease, and SUVmax ≥ 10 at other sites of disease ≥10mm (where there is no impact from partial voluming.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
-
Adequate bone marrow, hepatic and renal function documented within 28 days of registration, defined as:
- Haemoglobin ≥90 g/L independent of transfusions (no red blood cell transfusion in last 4 weeks)
- Absolute neutrophil count ≥1.5x109/L
- Platelets ≥100 x109/L
- Total bilirubin ≤1.5 x upper limit of normal (ULN) except for patients with known Gilbert's syndrome
- Aspartate transaminase (AST/SGOT) and alanine transaminase (ALT/SGPT) ≤2.5 × ULN or ≤5 × ULN for participants with liver metastases
- Serum creatinine ≤1.5 x ULN or a calculated creatinine clearance > 50mL/min (Cockcroft-Gault equation)
- Patients must have a life expectancy ≥ 24 weeks.
- Willing and able to comply with all study requirements, including treatment, timing and/or nature of required assessments
- Signed, written informed consent.
Exclusion
- Prostate cancer with known significant sarcomatoid, spindle cell or neuroendocrine cell components, or metastasis of other cancers to the prostate.
- 18F-FDG-PET/CT SUVmax ≥10 at a site of measurable disease with no concurrent PSMA expression > 10mm
- Prior treatment with anti-PD1, anti-PD-L1/L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T cell co-stimulation or checkpoint pathways.
- Patients must not have had more than one line of chemotherapy. If a patient has had docetaxel chemotherapy for hormone sensitive or castrate resistant setting, this will be considered one line.
- Prior treatment with 177Lu-PSMA.
- Patients with active, known, or suspected autoimmune disease. Sjogren's syndrome is considered an autoimmune disease. Exceptions: Patients with vitiligo, type I diabetes mellitus, residual hypothyroidism due to an autoimmune condition only requiring hormone replacement, or conditions not expected to recur in the absence of an external trigger, may be eligible.
- Patients with a condition requiring systemic treatment with either corticosteroids (>10mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of registration. Inhaled or topical steroids, and adrenal replacement doses ≤ 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
- Participants must have recovered from all AE due to previous therapies to ≤Grade 1 or baseline. Participants with ≤ Grade 2 neuropathy may be eligible.
- Active malignancies within the previous 2-years with >30% probability of recurrence within 1 year. Melanoma in situ, basal cell or squamous cell carcinomas of skin, are permitted.
- Significant infection, including chronic active hepatitis B, hepatitis C, or HIV. Testing for these is not mandatory unless clinically indicated.
- Radiation or surgery within 2 weeks of randomisation.
- Previous history of interstitial lung disease or non-infectious pneumonitis.
- Administration of a live vaccine within 30 days prior to the first dose of study drug.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Inadequate contraception. Men must have been surgically sterilised or use a (double if required) barrier method of contraception.
Inclusion
- Your cancer has spread to other parts of the body (metastatic) or has grown into nearby parts of the body (locally advanced).
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
Exclusion
- You have been diagnosed with a prior or secondary type of cancer.
- You have certain types of non-cancer medical conditions.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ClinicalTrials.gov *. View further details about this trial on the registry via the links below:
Trial sponsor
Bristol-Myers Squibb (BMS),Australian & New Zealand Urogenital and Prostate Cancer Trials Group Limited (ANZUP)
Scientific Title
Phase II Study of Radionuclide 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With MetastaticCastration Resistant Prostate Cancer (mCRPC)
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Peer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Peer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council to speak with an experienced health professional on 13 11 20.
Get support
Learn more about clinical trials through this collection of resources in languages other than English.
View information